These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19803878)

  • 1. The role of proteomics in the diagnosis and treatment of ovarian cancer.
    Tchabo NE; Guancial EA; Czechowicz JA; Kohn EC
    Womens Health (Lond); 2005 Nov; 1(3):365-74. PubMed ID: 19803878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
    Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
    Posadas EM; Davidson B; Kohn EC
    Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic studies of early-stage and advanced ovarian cancer patients.
    Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
    Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
    Tchabo NE; Liel MS; Kohn EC
    Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker discovery in ovarian cancer.
    Tung CS; Wong KK; Mok SC
    Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.
    Indovina P; Marcelli E; Pentimalli F; Tanganelli P; Tarro G; Giordano A
    Mass Spectrom Rev; 2013; 32(2):129-42. PubMed ID: 22829143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of oncoproteomics in the personalized management of cancer.
    Jain KK
    Expert Rev Proteomics; 2004 Jun; 1(1):49-55. PubMed ID: 15966798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of biomarkers for the ovarian cancer diagnosis.
    Zhang B; Cai FF; Zhong XY
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics and biomarkers for ovarian cancer diagnosis.
    Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
    Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
    Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
    J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.